<circle stroke="#1e77f9" class="srdi68r9" cx="25" cy="25" r="20" fill="none" stroke-width="5">

ImageneBio initiated with an Outperform at Leerink

PremiumThe Fly

10d ago

IMA

SNY

PremiumThe Fly

AstraZeneca, Amgen’s Tezspire approved in EU as add-on therapy

12d ago

Amgen, AstraZeneca announce FDA approval of Tezspire

PremiumThe Fly

17d ago

Amgen treatment of systemic sclerosis granted FDA orphan designation

PremiumThe Fly

18d ago

PremiumThe FlyTrump Weekly: Generics to be excluded from pharma tariff plan

24d ago

GoodRx, others in talks with White House to join TrumpRx, Reuters reports

The Fly

GoodRx, others in talks with White House to join TrumpRx, Reuters reports

25d ago

BMY

Amgen makes Repatha available through ‘AmgenNow’ direct to patient program

The Fly

Amgen makes Repatha available through ‘AmgenNow’ direct to patient program

28d ago

Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role

PremiumThe Fly

1M ago

PremiumThe Fly

Amgen’s Repatha meets primary Phase 3 endpoints in cardiovascular study

1M ago

Amgen announces $650M expansion of U.S. manufacturing network

PremiumThe Fly

1M ago

Pfizer gains ‘impressive obesity portfolio’ with Metsera deal, says BofA

PremiumThe Fly

1M ago

LLY

NVO

PremiumThe FlyAmgen call buyer realizes 206% same-day gains

1M ago

AstraZeneca, Amgen’s Tezspire recommended for approval in EU

The Fly

AstraZeneca, Amgen’s Tezspire recommended for approval in EU

1M ago

Amgen call volume above normal and directionally bullish

The Fly

Amgen call volume above normal and directionally bullish

1M ago

Biotech Alert: Searches spiking for these stocks today

PremiumThe Fly

2M ago

Biotech Alert: Searches spiking for these stocks today

SMMT

PremiumThe Fly

2M ago

Amgen, Kyowa Kirin announce preliminary results from ASCEND study

SMMT

PremiumThe Fly

2M ago

Private Markets: Anthropic raises $13B Series F at $183B post-money valuation

PremiumThe Fly

2M ago

PremiumThe FlySanofi’s ‘disappointing’ atopic dermatitis data sends Nektar higher

2M ago

SNY

Sanofi’s ‘disappointing’ results to boost Regeneron shares, says Raymond James

The Fly

Sanofi’s ‘disappointing’ results to boost Regeneron shares, says Raymond James

2M ago

SNY

Amgen’s Strategic Focus and Portfolio Strength Justify Buy Rating Despite Bemarituzumab Challenges

Ratings

Amgen’s Strategic Focus and Portfolio Strength Justify Buy Rating Despite Bemarituzumab Challenges

2M ago